The Inflation Reduction Act limits the annual out-of-pocket drug costs for Medicare Beneficiaries. As of January 1, 2025, the annual out-of-pocket maximum is $2,000 annually.
The inflation reduction act puts a cap on the cost of medications at $2,000 for the year which is a big reduction. There is also a payment plan you can choose to participate in which allows you to stretch out the payments throughout the year to help make it easier to pay large copayments up front until you reach the cap.
by introducing a $2,000 cap on out-of-pocket prescription drug costs. This means enrollees will not pay more than $2,000 out-of-pocket for their covered Part D drugs in 2025, including deductibles, copays, and coinsurance. The catastrophic coverage phase, where cost-sharing was previously eliminated, will now be entered once an enrollee's out-of-pocket spending reaches this $2,000 cap.
Starting in 2025, your Medicare Part D drug costs will be capped at $2,000 a year, and insulin will be no more than $35 a month. Plus, Medicare can now negotiate prices on certain high-cost medications, which should help keep your costs down.
The inflation reduction act helped to eliminate the Doughnut hole. Most carriers added deductibles to certain tiers to help cover the cost of the drugs.